MIAMI--(BUSINESS WIRE)--Aug. 9, 2006--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN - News) today announced financial results for the three-month and six-month periods ended June 30, 2006, and provided an update on its business and prospects. “The second quarter included a landmark achievement for Noven,” said Robert C. Strauss, Noven’s President, CEO & Chairman. “Daytrana(TM), the first and only patch for ADHD, was approved by the FDA in April 2006, and we shipped launch quantities in May and June. Approval triggered our receipt of a $50 million milestone payment, bringing our cash and short term investments at mid-year to $126 million.”
